Infanrix (Dtpa)

Diphtheria and tetanus toxoids and acellular pertussis vaccine, the active ingredient in Infanrix, is a vaccine presented as an injectable suspension for intramuscular use. It prevents diphtheria, tetanus and pertussis in infants and children. GNH USA supplies Infanrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix is a vaccine that targets bacterial toxins and pertussis antigens to prevent specific infectious diseases.

- Diphtheria: provides active immunity that prevents diphtheria infection. - Tetanus: induces antibodies that protect against tetanus caused by Clostridium tetani. - Pertussis: creates immunity that reduces the risk of whooping cough in infants and young children.

Common Side Effects: - Pain, redness or swelling at the injection site. - Low‑grade fever within 24‑48 hours. - Irritability or fussiness in infants. - Loss of appetite. - Mild headache. - Temporary soreness of the arm.

Serious or Rare Side Effects: - Anaphylactic reaction with difficulty breathing. - Seizures or convulsions. - Persistent high fever. - Encephalopathy or neurological symptoms. - Hypotonic‑hyporesponsive episodes. - Severe allergic rash or angioedema.

Infanrix should be administered only after evaluating the individual's health status and vaccine history. - Contraindication: severe allergic reaction to any component of the vaccine. - Not for infants younger than six weeks of age. - Delay vaccination if the child has a moderate or severe acute illness. - Use with caution in immunocompromised patients; response may be reduced. - Observe the child for at least 15 minutes after injection for signs of serious reaction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix may interact with other immunizations or immune‑modulating therapies.

Major Interactions (Avoid): - Live viral vaccines administered within four weeks before or after Infanrix. - Immunoglobulin or blood products containing antibodies given within three months. - High‑dose immune globulin therapy within three months of vaccination.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids that may blunt antibody response. - Ongoing immunosuppressive therapy (e.g., chemotherapy, biologics). - Chronic illnesses that could affect immune competence. - Concurrent administration of other non‑live vaccines may require spacing. - Anticonvulsant medications may mask febrile reactions.